As of 2026-04-01, the Intrinsic Value of AcelRx Pharmaceuticals Inc (ACRX) is 9.56 USD. This ACRX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.86 USD, the upside of AcelRx Pharmaceuticals Inc is 1,011.40%.
The range of the Intrinsic Value is 8.13 - 11.78 USD
Based on its market price of 0.86 USD and our intrinsic valuation, AcelRx Pharmaceuticals Inc (ACRX) is undervalued by 1,011.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 8.13 - 11.78 | 9.56 | 1011.4% |
| DCF (Growth 10y) | 8.94 - 12.78 | 10.46 | 1115.8% |
| DCF (EBITDA 5y) | 9.14 - 10.99 | 9.89 | 1049.5% |
| DCF (EBITDA 10y) | 9.65 - 12.17 | 10.70 | 1144.7% |
| Fair Value | -31.50 - -31.50 | -31.50 | -3,763.31% |
| P/E | (21.45) - 13.16 | (4.97) | -678.5% |
| EV/EBITDA | (7.81) - 15.66 | 3.36 | 290.7% |
| EPV | (12.96) - (18.02) | (15.49) | -1900.7% |
| DDM - Stable | (6.57) - (13.10) | (9.84) | -1243.7% |
| DDM - Multi | 4.19 - 6.78 | 5.20 | 504.7% |
| Market Cap (mil) | 14.58 |
| Beta | 1.74 |
| Outstanding shares (mil) | 16.95 |
| Enterprise Value (mil) | 1.18 |
| Market risk premium | 5.00% |
| Cost of Equity | 11.54% |
| Cost of Debt | 7.99% |
| WACC | 9.92% |